ABSTRACT
A recent guideline recommends therapeutic drug monitoring for risperidone, paliperidone and olanzapine, which are frequently used second-generation antipsychotics. We developed a simple high-performance liquid chromatography-tandem mass spectrometry coupled with an online solid-phase extraction method that can be used to measure risperidone, paliperidone and olanzapine using small (40 µL) samples. The analytes were extracted from serum samples automatically pre-concentrated and purified by C8 (5 µm, 2.1 × 30 mm) solid-phase extraction cartridges, then chromatographed on an Xbidge™ C18 column (3.5 µm, 100 × 2.1 mm) thermostatted at 30°C with a mobile phase consisting of 70% acetonitrile and 30% ammonium hydroxide 1% solution at an isocratic flow rate of 0.3 mL/min, and detected with tandem mass spectrometry. The assay was validated in the concentration range from 2.5 to 160 ng/mL. Intra- and inter-day precision for all analytes was between 1.1 and 8.2%; method accuracy was between 6.6 and 7.6%. The risperidone and paliperidone assay was compared with a high-performance liquid chromatography-ultraviolet assay currently used in our hospital for risperidone and paliperidone therapeutic drug monitoring, and the results of weighted Deming regression analysis showed good agreement. For the olanzapine assay, we compared 20 samples in separate re-assays on different days; all the relative errors were within the 20% recommended limit.
Subject(s)
Benzodiazepines/blood , Chromatography, High Pressure Liquid/methods , Paliperidone Palmitate/blood , Risperidone/blood , Solid Phase Extraction/methods , Tandem Mass Spectrometry/methods , Benzodiazepines/chemistry , Benzodiazepines/isolation & purification , Drug Stability , Humans , Limit of Detection , Linear Models , Olanzapine , Paliperidone Palmitate/chemistry , Paliperidone Palmitate/isolation & purification , Reproducibility of Results , Risperidone/chemistry , Risperidone/isolation & purificationABSTRACT
An accurate, rapid, and sensitive method for the determination of risperidone and 9-hydroxyrisperidone in urine samples was developed by combining water-compatible magnetic molecularly imprinted solid-phase extraction with high performance liquid chromatography. Several variables relating to the efficiency of magnetic solid phase extraction were optimized, including the amount of adsorbent, adsorption time, type of elution solvent, and desorption time. The analytical performance of this method was validated under the optimized conditions. The linearity for risperidone and 9-hydroxyrisperidone was obtained in the range 1-2000ngmL-1 with correlation coefficient ≥ 0.991. Limits of detection of risperidone and 9-hydroxyrisperidone are 0.21ngmL-1 and 0.24ngmL-1, respectively. Recoveries at three spike levels (10, 100, and 1000ngmL-1) ranged from 94.6% to 102.4% with relative standard deviations (%) ≤ 5.3. These results confirmed that this method can be successfully and facilely used to analyze the multi-residues of risperidone and 9-hydroxyrisperidone in urine samples with high efficiency and good sensitivity.
Subject(s)
Molecular Imprinting , Paliperidone Palmitate/isolation & purification , Polymers/chemistry , Risperidone/isolation & purification , Chromatography, High Pressure Liquid , Humans , Magnetics , Microscopy, Electron , Paliperidone Palmitate/chemistry , Paliperidone Palmitate/urine , Reproducibility of Results , Risperidone/chemistry , Risperidone/urine , Solid Phase Extraction/methods , Water/chemistryABSTRACT
One unknown impurity (degradation product) present at a level below 0.1% in the initial samples increased to a level of 0.5% in 6M/40 degrees C/75% RH stability samples of risperidone tablets was detected by gradient reverse-phase high-performance liquid chromatography (HPLC). This impurity was isolated using reverse-phase preparative liquid chromatography. Based on the spectral data the structure of this impurity is characterized as 3-[2-[4-[6-fluoro-1,3-benzoxazol-2-yl]piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a] pyrimidin-4-one. Structural elucidation of this impurity by spectral data ((1)H NMR, (13)C NMR, DEPT, MS and IR), formation and mechanism has been discussed in detail.
Subject(s)
Drug Contamination , Isoxazoles/chemistry , Risperidone/analogs & derivatives , Risperidone/chemistry , Antipsychotic Agents/chemistry , Chromatography, High Pressure Liquid/methods , Drug Stability , Hot Temperature , Isoxazoles/isolation & purification , Light , Magnetic Resonance Spectroscopy/methods , Mass Spectrometry/methods , Models, Chemical , Molecular Structure , Risperidone/isolation & purification , TabletsABSTRACT
The HPLC semipreparative enantioseparation of 9-hydroxyrisperidone (9-OHRisp) was studied by optimizing various experimental conditions: the nature of the chiral stationary phase (CSP), mobile phase composition, temperature and analyte loading. This semipreparative enantioseparation was successfully completed using the polysaccharide Chiralcel OJ chiral stationary phase and a n-hexane/ethanol/methanol (50/35/15, v/v/v) ternary mobile phase. To assess the enantiomeric purity of both isolated isomers, three analytical methods using UV detection were developed and validated: one CE method using dual cyclodextrin mode and two HPLC methods using either the Chiralcel OJ CSP in normal-phase mode or the alpha-acid glycoprotein (alpha-AGP) CSP in reversed-phase mode. The three methods make it possible to obtain excellent enantioseparations (R(s) >3) with analysis times lower than 15 min, and the calculated limits of detection allow for the determination of minor enantiomeric impurities (0.1%). Enantiomeric purity obtained for dextrorotatory and levorotatory enantiomers was superior to 99.9% and equal to 98.9%, respectively, which proved the success of the semipreparative enantioseparation. A brief comparison of the performances of the analytical methods completes this work.
